Aldeyra The
$ 1.71
1.18%
11 Jun - close price
- Market Cap 103,149,000 USD
- Current Price $ 1.71
- High / Low $ 1.73 / 1.66
- Stock P/E N/A
- Book Value 0.70
- EPS -0.45
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.22 %
- ROE -0.52 %
- 52 Week High 6.17
- 52 Week Low 1.07
About
Aldeyra Therapeutics, Inc., a biotechnology company, develops and markets drugs for immune-mediated systemic and eye diseases. The company is headquartered in Lexington, Massachusetts.
Analyst Target Price
$7.60
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-02-27 | 2025-11-05 | 2025-08-07 | 2025-05-14 | 2025-02-28 | 2024-11-07 | 2024-08-01 | 2024-05-02 | 2024-03-07 | 2023-11-03 | 2023-08-03 |
| Reported EPS | -0.06 | -0.11 | -0.13 | -0.16 | -0.17 | -0.27 | -0.25 | -0.28 | -0.14 | -0.08 | -0.14 | -0.15 |
| Estimated EPS | -0.12 | -0.155 | -0.16 | -0.19 | -0.244 | -0.22 | -0.26 | -0.14 | -0.11 | -0.14 | -0.25 | -0.3 |
| Surprise | 0.06 | 0.045 | 0.03 | 0.03 | 0.074 | -0.05 | 0.01 | -0.14 | -0.03 | 0.06 | 0.11 | 0.15 |
| Surprise Percentage | 50% | 29.0323% | 18.75% | 15.7895% | 30.3279% | -22.7273% | 3.8462% | -100% | -27.2727% | 42.8571% | 44% | 50% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.08 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ALDX
2026-06-11 20:09:28
Aldeyra Therapeutics director Neal Walker received two new stock option grants, according to a Form 4 SEC filing. These grants involve options for 3,318 and 70,000 shares of common stock, both with an exercise price of $1.72 per share. The options become fully exercisable one year after the grant date, contingent on his continuous service on the Board and Compensation Committee.
2026-06-11 20:09:28
Aldeyra Therapeutics director Darlene M. Deptula-Hicks has filed an initial Form 3, establishing her status as a reporting person with the company. This regulatory filing indicates her beneficial ownership for insider purposes but does not report any stock transactions or option exercises. The Form 3 clarifies that Deptula-Hicks is a director of Aldeyra Therapeutics and holds no derivative securities or has engaged in any buying or selling of ALDX shares as part of this initial statement.
2026-06-11 20:09:28
Aldeyra Therapeutics director Gary M. Phillips has received three new stock option grants, allowing him to purchase 70,000, 6,636, and 4,977 shares of common stock at an exercise price of $1.72 per share. These options will become fully exercisable on the one-year anniversary of the grant date, provided he continues his service on the Board and its Compensation and Audit Committees. The grants are compensation for his roles and are set to expire on June 8, 2036.
2026-06-10 12:38:51
Aldeyra Therapeutics CEO, Todd Brady, recently purchased US$418k worth of company stock at US$1.67 per share, increasing his holding by 18%. This purchase was the largest insider buy in the last year, indicating optimism among company leadership. While insider ownership is only 3.6%, recent buying trends suggest insiders
2026-06-10 11:39:46
Aldeyra Therapeutics' appointment of Darlene Deptula-Hicks to its Board of Directors is a strategic move to enhance financial stewardship and aid potential commercialization, especially following the March 2026 Complete Response Letter for reproxalap. Ms. Deptula-Hicks' extensive background in biotech IPOs, capital raising, and M&A, coupled with her experience as a CFO, is crucial for Aldeyra's future funding and growth, as the company faces regulatory hurdles, a shrinking workforce, and the need for significant capital to advance its pipeline. Her expertise will be vital in navigating the complexities of commercializing reproxalap and other therapies despite the current operational and financial challenges.
2026-06-10 06:09:48
Aldeyra Therapeutics, a biotechnology company focused on immune-mediated diseases, has appointed Darlene Deptula-Hicks to its board of directors. Ms. Deptula-Hicks brings over 30 years of experience in the life sciences sector, including senior executive and CFO roles in public and private companies. Her expertise in capital raises, strategic partnerships, and M&A transactions is expected to support Aldeyra as it moves towards potential commercialization of its therapies.
